I-Therapeutix Inc.
This article was originally published in Start Up
Executive Summary
I-Therapeutix is developing a hydrogel-based surgical sealant for ophthalmic surgery, and hydrogel-based formulations of existing ophthalmic drugs. To get to early revenues, I-Therapeutix will debut with an ocular bandage designed to improve outcomes in corneal and retinal surgeries. But an enormous market lies ahead for the start-up: there's a need to improve the delivery of drugs for glaucoma, today, the largest ophthalmic drug market, affecting 70 million people worldwide, and constituting a US market worth $1.7 billion.